BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu C, Xia R, Zhang X, Li T, Ye Y, Li G, He R, Li Z, Lin Q, Zheng S, Chen R. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Mol Cancer 2022;21:24. [PMID: 35045883 DOI: 10.1186/s12943-022-01501-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Seimiya T, Otsuka M, Fujishiro M. Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1023332] [Reference Citation Analysis]
2 Li W, Liu Z, Cen X, Xu J, Zhao S, Wang B, Zhang W, Qiu M. Integrated analysis of fibroblasts molecular features in papillary thyroid cancer combining single-cell and bulk RNA sequencing technology. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1019072] [Reference Citation Analysis]
3 Yan T, Tian X, Liu F, Liu Q, Sheng Q, Wu J, Jiang S. The emerging role of circular RNAs in drug resistance of non-small cell lung cancer. Front Oncol 2022;12:1003230. [DOI: 10.3389/fonc.2022.1003230] [Reference Citation Analysis]
4 Shen C, Li Z, Zhang Y, Zhang Z, Wu Z, Da L, Yang S, Wang Z, Zhang Y, Qie Y, Zhao G, Lin Y, Huang S, Zhou M, Hu H. Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancer. Front Oncol 2022;12:1018285. [DOI: 10.3389/fonc.2022.1018285] [Reference Citation Analysis]
5 Deng D, Patel R, Chiang C, Hou P. Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance. Cells 2022;11:2952. [DOI: 10.3390/cells11192952] [Reference Citation Analysis]
6 Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C, Zhang J, Wang J, Liu Y. Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications. Front Oncol 2022;12:951864. [PMID: 36059609 DOI: 10.3389/fonc.2022.951864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shi Y, Shen M, Yang Y, Qiu J. CircDUSP22 Overexpression Restrains Pancreatic Cancer Development via Modulating miR-1178-3p and Downstream BNIP3. Biochem Genet 2022. [PMID: 36063260 DOI: 10.1007/s10528-022-10275-8] [Reference Citation Analysis]
8 Lu Y, Zhou S, Cheng G, Ruan Y, Tian Y, Lv K, Han S, Zhou X, Ding X. CircLMTK2 Silencing Attenuates Gemcitabine Resistance in Pancreatic Cancer by Sponging miR-485-5p and to Target PAK1. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/1911592] [Reference Citation Analysis]
9 Zhang Y, Xing Z, Liu T, Tang M, Mi L, Zhu J, Wu W, Wei T. Targeted therapy and drug resistance in thyroid cancer. European Journal of Medicinal Chemistry 2022;238:114500. [DOI: 10.1016/j.ejmech.2022.114500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zeng R, Tong C, Xiong X. The Molecular Basis and Therapeutic Potential of Leukemia Inhibitory Factor in Cancer Cachexia. Cancers (Basel) 2022;14:2955. [PMID: 35740622 DOI: 10.3390/cancers14122955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Richards KE, Xiao W, Hill R, On Behalf Of The Usc Pancreas Research Team. Cancer-Associated Fibroblasts Confer Gemcitabine Resistance to Pancreatic Cancer Cells through PTEN-Targeting miRNAs in Exosomes. Cancers (Basel) 2022;14:2812. [PMID: 35681792 DOI: 10.3390/cancers14112812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfarouk KO, Cardone RA. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers (Basel) 2022;14:2486. [PMID: 35626089 DOI: 10.3390/cancers14102486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]